To include your compound in the COVID-19 Resource Center, submit it here.

Zevalin ibritumomab tiuxetan: Phase III data; marketed

In a Phase III trial in 143 patients with relapsed or refractory

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE